Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

281. The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST)

The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST) The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST). The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST). Rubin GJ, Bakhshi S, Amlôt R, Fear N, Potts HWW (...) , Michie S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rubin GJ, Bakhshi S, Amlôt R, Fear N, Potts HWW, Michie S. The design of a survey questionnaire to measure perceptions and behaviour during an influenza pandemic: the Flu TElephone Survey Template (FluTEST). Health Services and Delivery Research 2014; 2(41) Authors' objectives During

2014 Health Technology Assessment (HTA) Database.

282. Amantadine and rimantadine for influenza A in children and the elderly. (Abstract)

Amantadine and rimantadine for influenza A in children and the elderly. Influenza is an acute respiratory illness caused by influenza A and B viruses. Complications may occur, especially among children and the elderly.To assess the effectiveness and safety of amantadine and rimantadine in preventing, treating and shortening the duration of influenza A in children and the elderly.We searched CENTRAL (2014, Issue 9), MEDLINE (1966 to September week 4, 2014) and EMBASE (1980 to October 2014 (...) ).Randomised controlled trials (RCTs) or quasi-RCTs comparing amantadine and/or rimantadine with no intervention, placebo, other antivirals or different doses or schedules of amantadine or rimantadine in children and the elderly with influenza A.Two review authors independently assessed the search results. We extracted and analysed data using the standard Cochrane methodology.We identified 12 studies (2494 participants: 1586 children and 908 elderly) comparing amantadine and rimantadine with placebo

2014 Cochrane

283. The benefits of influenza vaccine in pregnancy for the fetus and the infant younger than six months of age

The benefits of influenza vaccine in pregnancy for the fetus and the infant younger than six months of age Influenza is a serious problem for infants <6 months of age, whose hospitalization rates for influenza and associated illness are comparable with rates in the elderly. Because influenza vaccines are not effective in this age group, the optimal evidence-based strategy is to administer trivalent inactivated influenza vaccines during pregnancy. Immunizing with trivalent inactivated (...) influenza vaccines in the second and third trimester is well studied and safe, not only providing protection for the pregnant woman and her infant <6 months of age, but also for the fetus by decreasing the risk for low birth weight. Key Words: ALRI; Cocooning; Influenza; TIV

2014 Canadian Paediatric Society

284. Peramivir for acute uncomplicated influenza in adults

Peramivir for acute uncomplicated influenza in adults Peramivir for acute uncomplicated influenza in adults Peramivir for acute uncomplicated influenza in adults NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Peramivir for acute uncomplicated influenza in adults. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC (...) ). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cyclopentanes; Guanidines; Influenza, Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT. Tel: +44 121 414 7831 Email: nihrhsc@contacts.bham.ac.uk

2014 Health Technology Assessment (HTA) Database.

285. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. Full Text available with Trip Pro

Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. Human infections with avian influenza A/H7N9 have resulted in high morbidity and mortality in China.To compare safety and immunogenicity of different doses of influenza A/Shanghai/2/13 (H7N9) vaccine mixed with or without the MF59 adjuvant.Multicenter, randomized, double-blind, phase 2 trial at 4 US sites enrolled 700 adults aged 19 to 64 years beginning (...) or both 15 µg doses (n = 34 [35%; 95% CI, 25%-45%] vs n = 47 [47%; 95% CI, 37%-58%], respectively; P = .10). Recent receipt of seasonal influenza vaccination and older age were associated with attenuated response. No vaccine-related serious adverse events occurred. Solicited postvaccination symptoms were generally mild with more local symptoms seen in participants who received the adjuvant.Point-of-use mixing and administration of 2 doses of H7N9 vaccine at the lowest tested antigen dose with MF59

2014 JAMA Controlled trial quality: predicted high

286. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. Full Text available with Trip Pro

Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. The need to respond quickly to potential influenza pandemics is important. Immunologic priming (initial presentation of an antigen to allow antibody responses on revaccination) with vaccine directed toward an older avian influenza H5 strain might lead to secondary antibody responses to a single dose of more current H5 avian influenza vaccine.To assess priming with the older avian (...) influenza A/Vietnam/1203/2004(H5N1) (Vietnam) vaccine and to conduct dose-response studies with vaccine directed against the more contemporary H5N1 avian influenza virus, influenza A/Anhui/01/2005 (Anhui).Multicenter US randomized clinical trial beginning in June 2010 with follow-up continuing through October 2011 enrolling 72 healthy adults who were vaccinated 1 year previously with the Vietnam vaccine and 565 vaccine-naive adults.Participants who were previously vaccinated with 90 µg of unadjuvanted

2014 JAMA Controlled trial quality: predicted high

287. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Full Text available with Trip Pro

Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Chronic bronchitis and chronic obstructive pulmonary disease (COPD) are serious conditions in which patients are predisposed to viral and bacterial infections resulting in potentially fatal acute exacerbations. COPD is defined as a lung disease characterised by obstruction to lung airflow that interferes with normal breathing. Antibiotic therapy has (...) not been particularly useful in eradicating bacteria such as non-typeable Haemophilus influenzae (NTHi) because they are naturally occurring flora of the upper respiratory tract in many people. However, they can cause opportunistic infection. An oral NTHi vaccine has been developed to protect against recurrent infective acute exacerbations in chronic bronchitis.To assess the effectiveness of an oral, whole-cell, non-typeable H. influenzae (NTHi) vaccine in protecting against recurrent episodes of acute

2014 Cochrane

288. Interventions to increase influenza vaccination rates of those 60 years and older in the community. Full Text available with Trip Pro

Interventions to increase influenza vaccination rates of those 60 years and older in the community. The effectiveness of interventions to increase the uptake of influenza vaccination in people aged 60 and older is uncertain.To assess access, provider, system and societal interventions to increase the uptake of influenza vaccination in people aged 60 years and older in the community.We searched CENTRAL (2014, Issue 5), MEDLINE (January 1950 to May week 3 2014), EMBASE (1980 to June 2014 (...) ), AgeLine (1978 to 4 June 2014), ERIC (1965 to June 2014) and CINAHL (1982 to June 2014).Randomised controlled trials (RCTs) of interventions to increase influenza vaccination uptake in people aged 60 and older.Two review authors independently assessed study quality and extracted influenza vaccine uptake data.This update identified 13 new RCTs; the review now includes a total of 57 RCTs with 896,531 participants. The trials included community-dwelling seniors in high-income countries. Heterogeneity

2014 Cochrane

289. Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-y

Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-y Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk (...) 18- to 64-year-olds Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds Nicholson KG, Abrams KR, Batham S, Medina MJ, Warren FC, Barer M, Bermingham A, Clark TW, Latimer N, Fraser M, Perera N, Rajakumar K, Zambon M Record Status This is a bibliographic record of a published health

2014 Health Technology Assessment (HTA) Database.

290. Intranasal influenza vaccine for children (Fluenz): it is better to keep to the injectable vaccine

Intranasal influenza vaccine for children (Fluenz): it is better to keep to the injectable vaccine Prescrire IN ENGLISH - Spotlight ''Intranasal influenza vaccine for children (Fluenz°): it is better to keep to the injectable vaccine'', 1 September 2013 {1} {1} {1} | | > > > Intranasal influenza vaccine for children (Fluenz°): it is better to keep to the injectable vaccine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |    (...) |   |   |   |   |   |  Spotlight Intranasal influenza vaccine for children (Fluenz°): it is better to keep to the injectable vaccine In children where vaccination against influenza is advisable, the live attenuated influenza intranasal vaccine has not been evaluated in terms of influenza complications. It is better to keep to the injectable vaccine. Vaccination of children against influenza is offered when there is an increased risk of complications: severe

2014 Prescrire

291. Health and Economic Benefits of Early Vaccination and Nonpharmaceutical Interventions for a Human Influenza A (H7N9) Pandemic: A Modeling Study. Full Text available with Trip Pro

Health and Economic Benefits of Early Vaccination and Nonpharmaceutical Interventions for a Human Influenza A (H7N9) Pandemic: A Modeling Study. Vaccination for the 2009 pandemic did not occur until late in the outbreak, which limited its benefits. Influenza A (H7N9) is causing increasing morbidity and mortality in China, and researchers have modified the A (H5N1) virus to transmit via aerosol, which again heightens concerns about pandemic influenza preparedness.To determine how quickly (...) vaccination should be completed to reduce infections, deaths, and health care costs in a pandemic with characteristics similar to influenza A (H7N9) and A (H5N1).Dynamic transmission model to estimate health and economic consequences of a severe influenza pandemic in a large metropolitan city.Literature and expert opinion.Residents of a U.S. metropolitan city with characteristics similar to New York City.Lifetime.Societal.Vaccination of 30% of the population at 4 or 6 months.Infections and deaths averted

2014 Annals of Internal Medicine

292. The immune response and within-host emergence of pandemic influenza virus. (Abstract)

The immune response and within-host emergence of pandemic influenza virus. Zoonotic influenza viruses that are a few mutations away from pandemic viruses circulate in animals, and can evolve into airborne-transmissible viruses in human beings. Paradoxically, such viruses only occasionally emerge in people; the four influenza pandemics that occurred in the past 100 years were caused by zoonotic viruses that acquired efficient transmissibility. Emergence of a pandemic virus in people can happen (...) when transmissible viruses evolve in individuals with zoonotic influenza and replicate to titres allowing transmission. We postulate that this step in the genesis of a pandemic virus only occasionally occurs in human beings, because the immune response triggered by zoonotic influenza virus also controls transmissible mutants that emerge during infection. Therefore, an impaired immune response might be needed for within-host emergence of a pandemic virus and replication to titres allowing

2014 Lancet

293. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Full Text available with Trip Pro

Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. To describe the potential benefits and harms of zanamivir.Systematic review of clinical study reports of randomised placebo controlled trials and regulatory informationClinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers.Randomised placebo controlled trials in adults and children who had confirmed (...) or suspected exposure to natural influenza.Time to first alleviation of symptoms, influenza outcomes and complications, admissions to hospital, and adverse events in the intention to treat (ITT) population.We included 28 trials in stage 1 (judgment of appropriate study design) and 26 in stage 2 (formal analysis). For treatment of adults, zanamivir reduced the time to first alleviation of symptoms of influenza-like illness by 0.60 days (95% confidence interval 0.39 to 0.81, P<0.001, I(2)=9%), which equates

2014 BMJ

294. Risk of Invasive Haemophilus influenzae Infection During Pregnancy and Association With Adverse Fetal Outcomes. Full Text available with Trip Pro

Risk of Invasive Haemophilus influenzae Infection During Pregnancy and Association With Adverse Fetal Outcomes. Unencapsulated Haemophilus influenzae frequently causes noninvasive upper respiratory tract infections in children but can also cause invasive disease, especially in older adults. A number of studies have reported an increased incidence in neonates and suggested that pregnant women may have an increased susceptibility to invasive unencapsulated H. influenzae disease.To describe (...) the epidemiology, clinical characteristics, and outcomes of invasive H. influenzae disease in women of reproductive age during a 4-year period.Public Health England conducts enhanced national surveillance of invasive H. influenzae disease in England and Wales. Clinical questionnaires were sent prospectively to general practitioners caring for all women aged 15 to 44 years with laboratory-confirmed invasive H. influenzae disease during 2009-2012, encompassing 45,215,800 woman-years of follow-up. The final

2014 JAMA

295. Vaccines for preventing influenza in healthy adults. (Abstract)

Vaccines for preventing influenza in healthy adults. Different types of influenza vaccines are currently produced worldwide. Vaccination of pregnant women is recommended internationally, while healthy adults are targeted in North America.To identify, retrieve and assess all studies evaluating the effects (efficacy, effectiveness and harm) of vaccines against influenza in healthy adults, including pregnant women.We searched the Cochrane Central Register of Controlled Trials (CENTRAL (...) ) (The Cochrane Library 2013, Issue 2), MEDLINE (January 1966 to May 2013) and EMBASE (1990 to May 2013).Randomised controlled trials (RCTs) or quasi-RCTs comparing influenza vaccines with placebo or no intervention in naturally occurring influenza in healthy individuals aged 16 to 65 years. We also included comparative studies assessing serious and rare harms.Two review authors independently assessed trial quality and extracted data.We included 90 reports containing 116 data sets; among these 69 were

2014 Cochrane

296. Vaccines for preventing influenza in people with cystic fibrosis. (Abstract)

Vaccines for preventing influenza in people with cystic fibrosis. Viral respiratory tract infections in people with cystic fibrosis have a deteriorating effect on their lung function and disease progression. Annual influenza vaccination is therefore commonly recommended for people with cystic fibrosis.To assess the effectiveness of influenza vaccination for people with cystic fibrosis.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises (...) of references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also contacted the companies which market the influenza vaccines used in the trials to obtain further information about randomised controlled trials.Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register: 08 July 2013.All randomised and quasi-randomised trials (published

2014 Cochrane

297. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. (Abstract)

Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cystic fibrosis is the most common, life-threatening, recessively inherited disease of Caucasian populations. It is a multisystem disorder caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator protein which is important in producing sweat, digestive juices and mucus.The impaired or absent function of this protein results in the production of viscous mucus (...) within the lungs and an environment that is susceptible to chronic airway obstruction and pulmonary colonization by a range of pathogenic bacteria. Morbidity and mortality of cystic fibrosis is related to chronic pulmonary sepsis and its complications by these bacteria.Influenza can worsen the course of the disease in cystic fibrosis by increasing the risk of pneumonia and secondary respiratory complications. Antiviral agents form an important part of influenza management and include

2014 Cochrane

298. Preventing and Controlling Influenza with Available Interventions. (Abstract)

Preventing and Controlling Influenza with Available Interventions. 24450860 2014 03 05 2014 02 27 1533-4406 370 9 2014 Feb 27 The New England journal of medicine N. Engl. J. Med. Preventing and controlling influenza with available interventions. 789-91 10.1056/NEJMp1400034 Uyeki Timothy M TM From the Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta. eng Journal Article 2014 01 22 United States N Engl J Med 0255562 0028-4793 0 Antiviral Agents 0 (...) Influenza Vaccines AIM IM Age Factors Antiviral Agents therapeutic use Disease Transmission, Infectious prevention & control Humans Influenza A Virus, H1N1 Subtype Influenza Vaccines Influenza, Human complications drug therapy prevention & control 2014 1 24 6 0 2014 1 24 6 0 2014 3 7 6 0 ppublish 24450860 10.1056/NEJMp1400034

2014 NEJM

299. Influenza Vaccination During Pregnancy

Influenza Vaccination During Pregnancy Influenza Vaccination During Pregnancy - ACOG Menu ▼ Influenza Vaccination During Pregnancy Page Navigation ▼ Number 732, April 2018 (Replaces Committee Opinion Number 608, September 2014) Committee on Obstetric Practice This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Immunization and Emerging Infections Expert Work Group and the Committee on Obstetric Practice in collaboration with Neil S. Silverman, MD (...) presented. Influenza Vaccination During Pregnancy ABSTRACT: Influenza vaccination is an essential element of prepregnancy, prenatal, and postpartum care because influenza can result in serious illness, including a higher chance of progressing to pneumonia, when it occurs during the antepartum or postpartum period. In addition to hospitalization, pregnant women with influenza are at increased risk of intensive care unit admission and adverse perinatal and neonatal outcomes. The Centers for Disease

2014 American College of Obstetricians and Gynecologists

300. Pregnancy outcomes associated with maternal influenza vaccination: systematic review and meta-analysis

Pregnancy outcomes associated with maternal influenza vaccination: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2014 PROSPERO